Company Analysis
Sign in

Nautilus Biotechnology, Inc. (NAUT)

Nasdaq: NAUT · Laboratory Analytical Instruments · Seattle, WA · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.4
◀ Past 4.6● Present 6.1▶ Future 5.1
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$59.0M+16.6%
Earnings per share$-0.47+16.1%
Operating cash flow-$50.7M+14.3%
Cash$13.4M-53.3%
Debtn/a
Shareholders’ equity$157M-24.8%
Shares, diluted126.3M+0.7%
Return on equity-37.6%
The recordfrom its filings
Filings in 202639
Newest filingNov 3 · SCHEDULE 13D/A
Annual reportFeb 26, 2026
Quarterly reportOct 27, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$100,000
Patents granted12
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$58.6MCash from operations -$52.5Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 27, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 27, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 18, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Sep 18, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form S-3
Shelf registration
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton NAUT · research, not advice